What is the 13F Pro Quality Score for ABCL?

13F Pro ranks AbCellera Biologics Inc. (ABCL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ABCL's current score at https://13fpro.ai/research/ABCL (free sign-up required for the full ranking).

Where does 13F Pro source ABCL data?

All AbCellera Biologics Inc. fundamentals and ownership data come directly from SEC EDGAR. AbCellera Biologics Inc. files with the SEC under CIK 1703057. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ABCL in?

AbCellera Biologics Inc. (ABCL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ABCL research updated on 13F Pro?

ABCL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AbCellera Biologics Inc.(ABCL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1703057 ABCL stock profile & AI dashboard →

13F Pro Quality Score

17.2/100

Rank #2,725 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

31.3/100

Profitability

3.5/100

Balance Sheet

14.7/100

Earnings Quality

30.0/100

Free Cash Flow

3.5/100

Institutional Flow

90.2/100

Revenue Scale

9.0/100

Dilution Risk

3.7/100

ABCL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AbCellera Biologics Inc. (ABCL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABCL at 17.2/100 on a 32-signal composite quality model, placing it at rank #2,725 of 2,879 stocks — the bottom half of the AI-ranked universe. ABCL scores in the top quartile across institutional flow (90.2). Areas of concern include profitability (3.5) and free cash flow (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AbCellera Biologics Inc. reports quarterly revenue of $8.3M, net income of $-43.2M, free cash flow of $-37.4M. Top institutional holders of ABCL by reported 13-F value include BAKER BROS. ADVISORS, Capital World Investors, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. ABCL trades on the Nasdaq exchange and files with the SEC under CIK 1703057. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABCL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AbCellera Biologics Inc. directly from SEC EDGAR. AbCellera Biologics Inc.'s 13F Pro composite quality score has ranged between 8 and 78 since 2022, currently 17.2 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about AbCellera Biologics Inc.

Quirks, history, and lore behind ABCL — the kind of stuff that makes a stock memorable.

1
The Basics
Canadian biotechnology company · listed on Nasdaq · headquartered in Vancouver, British Columbia · operates in the drug discovery space.
2
The Numbers
A small-cap biotech with revenue in the range of a few hundred million dollars annually — most of it flowing from partnership and licensing deals rather than approved drugs on pharmacy shelves.
3
The History
Founded around 2012, it grew out of research at the University of British Columbia and went public in 2021, riding the wave of pandemic-era biotech enthusiasm.
4
The Secret
Its core business is essentially a technology platform for hire — pharma giants pay it to rapidly discover and develop therapeutic antibodies they could never find as fast on their own.
5
The Lore
Its platform helped identify antibody candidates against COVID-19 at record speed, putting this relatively young Canadian upstart on the global pandemic response map.
6
The Giveaway
The name is practically a lab coat in letter form — "Ab" for antibody, plus a word meaning to multiply cells — a Vancouver antibody discovery engine that partners with the world's biggest drugmakers.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.3M

Net Income

Q1 2026

$-43.2M

Free Cash Flow

Q1 2026

$-37.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+160.6% YoY

$75.1MFY 2025

FY22 $485.4MFY23 $38.0MFY24 $28.8MFY25 $75.1M

Net Income

+10.1% YoY

$-146.4MFY 2025

FY22 $158.5MFY23 $-146.4MFY24 $-162.9MFY25 $-146.4M

Operating Income

+31.0% YoY

$-217.1MFY 2025

FY22 $216.5MFY23 $-237.2MFY24 $-314.8MFY25 $-217.1M

EPS (Diluted)

+10.9% YoY

$-0.49FY 2025

FY22 $0.50FY23 $-0.51FY24 $-0.55FY25 $-0.49

Total Assets

-0.3% YoY

$1.36BFY 2025

FY22 $1.54BFY23 $1.49BFY24 $1.36BFY25 $1.36B

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-20.9% YoY

$-131.3MFY 2025

FY22 $277.4MFY23 $-43.9MFY24 $-108.6MFY25 $-131.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$75.1M +160.6%	$28.8M -24.2%	$38.0M -92.2%	$485.4M +29.4%	$375.2M +60.9%	$233.2M
Net Income	$-146.4M +10.1%	$-162.9M -11.2%	$-146.4M -192.4%	$158.5M +3.3%	$153.5M +29.1%	$118.9M
Operating Income	$-217.1M +31.0%	$-314.8M -32.7%	$-237.2M -209.6%	$216.5M +5.9%	$204.4M +31.0%	$156.0M
EPS (Diluted)	$-0.49 +10.9%	$-0.55 -7.8%	$-0.51 -202.0%	$0.50 +4.2%	$0.48 +6.7%	$0.45
Total Assets	$1.36B -0.3%	$1.36B -8.6%	$1.49B -3.4%	$1.54B +16.9%	$1.32B +31.1%	$1.01B
Total Debt	—	—	—	—	—	$190.0K
Operating Cash Flow	$-131.3M -20.9%	$-108.6M -147.4%	$-43.9M -115.8%	$277.4M +13.4%	$244.6M +977.9%	$22.7M

AI Insight: ABCL Ratio Trends

AbCellera remains deeply unprofitable with negative returns across all metrics; Q4 2025 showed operating margin improvement but momentum reversed in Q1 2026.

• Operating margin improved sharply to -63.7% in Q4 2025, first visible margin data point; reverted to unmeasured in Q1 2026.

• ROIC deteriorated from -19.7% in Q2 2025 to -31.6% in Q3 2025, then recovered to -11.8% in Q4 2025 before worsening to -24.5% in Q1 2026.

• Net profit margin compressed to -181.7% on TTM basis; Q4 2025 NPM of -19.9% reflects substantial operational losses.

⚠ ROIC volatility (ranging -11.8% to -34.8% across nine quarters) signals unstable profitability and capital deployment challenges.

⚠ Q1 2026 ROA deteriorated to -13.2% versus Q4 2025's -2.6%, suggesting asset efficiency declined sharply post–Q4.

Get alerted when ABCL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AbCellera Biologics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ABCL

BAKER BROS. ADVISORS LP
$105.7M30,275,938 sh
Capital World Investors
$46.6M13,361,096 sh
TWO SIGMA INVESTMENTS, LP
$36.9M10,562,065 sh
TD Waterhouse Canada Inc.
$33.6M9,564,659 sh
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$26.4M7,575,476 sh
UBS Group AG
$14.7M4,209,052 sh
ArrowMark Colorado Holdings LLC
$14.3M4,105,095 sh
BlackRock, Inc.
$14.1M4,040,236 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$14.0M4,024,779 sh
GOLDMAN SACHS GROUP INC
$13.1M3,751,212 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$105.7M	30,275,938
Capital World Investors	$46.6M	13,361,096
TWO SIGMA INVESTMENTS, LP	$36.9M	10,562,065
TD Waterhouse Canada Inc.	$33.6M	9,564,659
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME	$26.4M	7,575,476
UBS Group AG	$14.7M	4,209,052
ArrowMark Colorado Holdings LLC	$14.3M	4,105,095
BlackRock, Inc.	$14.1M	4,040,236
DRIEHAUS CAPITAL MANAGEMENT LLC	$14.0M	4,024,779
GOLDMAN SACHS GROUP INC	$13.1M	3,751,212

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

ABT

ABBOTT LABORATORIES

Put ABCL on your watchlist

Track score changes the day AbCellera Biologics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ABCL a good stock to buy?

13F Pro's AI-powered analysis of AbCellera Biologics Inc. (ABCL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABCL are available on the ABCL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ABCL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABCL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AbCellera Biologics Inc.'s investment landscape.